Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | ESR1 | P03372 | 2/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.53 |
| ▸ | TACR2 | P21452 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SHBG | P04278 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.53 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30785014 | 0.98 | FFAR1 (0.59) | FFAR1HSD17B10TSHRHTR2AESR1 | |
| SCHEMBL6046904 | 0.98 | FFAR1 (0.59) | FFAR1HSD17B10TSHRHTR2AESR1 | |
| SCHEMBL1495032 | 0.92 | FFAR1 (0.61) | FFAR1HSD17B10TSHRHTR2AALDH1A1 | |
| SCHEMBL687158 | 0.92 | HSD17B10 (0.65) | FFAR1HSD17B10TSHRHTR2AESR1 | |
| SCHEMBL9329731 | 0.92 | HSD17B10 (0.65) | FFAR1HSD17B10TSHRHTR2AESR1 | |
| SCHEMBL9330376 | 0.92 | HSD17B10 (0.65) | FFAR1HSD17B10TSHRHTR2AESR1 | |
| SCHEMBL9330316 | 0.92 | HSD17B10 (0.65) | FFAR1HSD17B10TSHRHTR2AESR1 | |
| SCHEMBL9330328 | 0.92 | HSD17B10 (0.65) | FFAR1HSD17B10TSHRHTR2AESR1 | |
| SCHEMBL9327124 | 0.92 | HSD17B10 (0.65) | FFAR1HSD17B10TSHRHTR2AESR1 | |
| SCHEMBL9328135 | 0.92 | HSD17B10 (0.65) | FFAR1HSD17B10TSHRHTR2AESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0990943-A1 | An improved liquid crystal display device | Centre for Liquid Crystal Research (IN) | 2000-04-05 | — | — | EP | claimed |
| JP-11352525-A | — | — | None | — | — | JP | disclosed |
| US-7728014-B2 | Heteroaromatic compounds having sphingosine-1-phosphate (S1P) receptor agonist biological activity | ALLERGAN, INC. | 2010-06-01 | — | — | US | disclosed |
| EP-2066633-A1 | HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST AND/OR ANTAGONIST BIOLOGICAL ACTIVITY | Allergan, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-2064183-A2 | HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST BIOLOGICAL ACTIVITY | Allergan, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008030843-A1 | HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST AND/OR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008030838-A2 | HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20080064872-A1 | HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. | 2008-03-13 | — | — | US | disclosed |
| EP-0990943-B1 | An improved liquid crystal display device | CT FOR LIQUID CRYSTAL RES (IN) | 2007-08-22 | — | — | EP | disclosed |
| US-6558759-B2 | Formed with pair of transparent substrates, each having one of surfaces coated with transparent electroconductive material serving as electrode, nematic discotic material having negative anisotropy is sandwiched between forming cell | CENTRE FOR LIQUID CRYSTAL RESEARCH (ID) | 2003-05-06 | — | — | US | disclosed |
| US-20010046568-A1 | Liquid crystal display device | CENTRE FOR LIQUID CRYSTAL RESEARCH (IN) | 2001-11-29 | — | — | US | disclosed |
| EP-0990943-A1 | An improved liquid crystal display device | Centre for Liquid Crystal Research (IN) | 2000-04-05 | — | — | EP | disclosed |
| JP-H11352525-A | LIQUID CRYSTAL DISPLAY DEVICE | CENTER FOR LIQUID CRYSTAL RES | 1999-12-24 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064872-A1 | HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST BIOLOGICAL ACTIVITY | S1PR4, S1PR3, S1PR1 | FFAR1 23/4885HSD17B10 2161/4885TSHR 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.